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Abstract  
 
Objectives:  Combined oral contraceptives (COCs) decrease androgen levels, including 
testosterone (T), which may be associated with sexual dysfunction and mood complaints in 
some women. We have shown that co-administration of dehydroepiandrosterone (DHEA) to 
a drospirenone (DRSP) containing COC restored total T levels to baseline and free T levels 
by 47%. Here we describe the effects on sexual function, mood and quality of life of such an 
intervention. 
 
Study design: This was a randomized, double-blind, placebo-controlled study in 99 healthy 
COC starters. A COC containing 30 µg ethinylestradiol (EE) and 3 mg DRSP was used for 3 
cycles, followed by 6 cycles of the same COC combined with 50 mg/day DHEA or placebo. 
Subjects completed the Moos Menstrual Distress Questionnaire (MDQ), the McCoy Female 
Sexuality Questionnaire (MFSQ) and the short form of the Quality of Life Enjoyment and 
Satisfaction Questionnaire (Q-LES-Q). Safety and tolerability, including effects on skin were 
evaluated.  
 
Results: The addition of DHEA induced small, but significant improvements compared to 
placebo in the MDQ score for: Autonomic reactions during the menstrual (-2.0 vs 0.71; 
P=0.05) and the pre-menstrual phase  (-3.1 vs 2.9; P=0.01); and for Behavior during the 
inter-menstrual phase (-1.4 vs 3.6; P=0.02). A significant difference was found in the MDQ 
score for arousal during the pre-menstrual phase in favor of placebo (-5.0 vs 1.0; P=0.01). 
There were no statistically significant differences between groups for the MSFQ and Q-LES-
Q scores. DHEA co-administration resulted in an acceptable safety profile. DHEA negated 
the beneficial effect of the COC on acne according to the subjects’ self-assessment.  
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Conclusions: Co-administration with DHEA did not result in consistent improvements in 
sexual function, mood and quality of life indicators in women taking EE/DRSP. 
Retrospectively, the 50 mg dose of DHEA may be too low for this COC. 
 
Implications A well-balanced judgment of the clinical consequences of normalizing 
androgens during COC use may require complete normalization of free T.  
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Introduction  
 
The use of combined oral contraceptives (COCs) has been associated with negative effects on 
sexual function and mood in some women [1-9]. These side effects may result in 
discontinuation of COCs [7, 10-12], and may have an adverse impact on quality of life [13]. 
Androgens, including testosterone (T), are believed to play a key role in sexual function and 
mood, and androgen replacement therapy, such as transdermal testosterone, has been shown 
to improve symptoms such as well-being, mood and sexual desire in pre- and postmenopausal 
women with sexual dysfunction [14-18].  
COCs are known to reduce androgen levels, especially T [19, 20], although no 
consistent effect on mood and sexual function has been observed [3, 21-26]. However, 
reduced androgen levels may be an important factor contributing to COC-associated sexual 
dysfunction and mood complaints [27, 28]. Therefore, by normalizing androgen levels, 
especially T, the negative effects of COCs on sexual function and mood could be 
ameliorated. Maintaining physiological androgen levels in women using a COC may be 
achieved by the addition of the natural human adrenal hormone dehydroepiandrosterone 
(DHEA); DHEA is partially metabolized into T [29-31] and could be incorporated into a 
COC pill because it is orally bioavailable [32].  
 We have reported that daily co-administration of 50 mg DHEA to a drospirenone 
(DRSP) containing COC significantly increased total T levels and restored baseline levels, 
whereas the biologically active free T levels were normalized by 47% only [20]. Here, we 
describe the effect of DHEA co-administration on sexual function, mood, and quality of life 
in new COC users without sexual function or mood complaints. In doing so, we wished to 
determine (i) whether COC use alone would result in unfavorable effects on sexual function, 
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mood and/or quality of life and (ii) whether 6 cycles of treatment with DHEA would have a 
favorable effect on sexual function, mood and/or quality of life compared to placebo. 
 
Materials and Methods 
 
This was a randomized, double-blind, placebo-controlled study with a primary objective to 
assess the effects on androgen metabolism of the co-administration of DHEA in subjects 
using a drospirenone-ethinylestradiol (DRSP/EE) COC compared to a control group of 
subjects receiving a DRSP/EE COC alone [20]. Here we report on the secondary study 
objectives, which included evaluating the effects of 6 treatment cycles with DHEA or placebo 
on sexual function, mood, menstrual symptoms and quality of life. General safety and 
acceptability, including skin characteristics of DHEA co-adminstration were also evaluated. 
Study population, design, procedures and medication are as described in the manuscript 
reporting the endocrine effects of this study [20]. Briefly, healthy females who were sexually 
active, aged between 18 and 35 years, and had a body mass index (BMI) between 18 and 
35 kg/m
2 
were enrolled. All participants must not have taken a hormonal contraceptive for at 
least 3 months prior to the start of the study medication.  
 
Study design and procedures 
Eligible participants were randomized to a 30 µg EE and 3 mg DRSP COC with co-
administration of DHEA or placebo in a ratio of 1:1. The study consisted of a 3 cycle run-in 
period with COC use alone, followed by a 6 cycle treatment period in which participants 
continued COC use in combination with either DHEA or placebo. Each treatment cycle 
consisted of 28 days. During all treatment cycles participants took one tablet of the EE/DRSP 
COC from day 1 to day 21 followed by a pill-free period of 7 days. During the 6-cycle 
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treatment period, DHEA or placebo was used continuously, including during the pill-free 
period.  
 
Assessment of sexual function, mood, menstrual cycle symptoms and quality of life  
The clinical effect of COC use only and of DHEA co-administration on mood, quality of life, 
menstrual cycle symptoms and sexual function was evaluated using the following validated 
self-administered questionnaires: the Moos Menstrual Distress Questionnaire (MDQ) [33, 
34], the McCoy Female Sexuality Questionnaire (MFSQ) [35] and the short form of the 
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) [36]. These three 
questionnaires were completed at study visits before starting COC use (baseline), and at the 
end of cycles 3 (end of run-in period), 4, 6 and 9 (the treatment period) or at premature 
discontinuation. In this manuscript we have focused on reporting the change in scores from 
the end of the run-in period (Cycle 3) to the end of the treatment period (Cycle 9) in the 
DHEA group vs placebo group, in accordance with the study objectives and statistical 
analysis plan. Assessments were performed during the pill-free period, since most subjective 
complaints occur during that period of cyclic COC use [37, 38].  
MDQ 
The MDQ was used to assess menstrual cycle symptoms including those relating to sexual 
function and mood. The questionnaire addresses 47 symptoms on a six-point scale grouped in 
eight domains: Pain, Water retention, Autonomic reactions, Negative affect, Impaired 
concentration, Behavior change, Arousal and Control (Supplemental Table S1). Rating of 
menstrual cycle symptoms was completed by the subjects at each study visit for three phases 
of the cycle: most recent flow (menstrual phase); four days before flow (pre-menstrual 
phase); remainder of cycle (inter-menstrual phase). For all items, except the Arousal score, a 
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lower score indicates more positive symptoms or reactions, while Arousal scores positively 
when it increases. A score of 50 is the standard (SD10).  
MFSQ 
The MFSQ questionnaire is designed to measure major aspects of female sexuality and 
particularly those aspects of female sexuality likely to be affected by changes in sex hormone 
levels. The MFSQ assesses sexual functioning using 19 items on a 7-point scale, where a 
higher score means a better result (higher quality of life). It is divided into 6 domains: Global 
score; Sexual interest; Satisfaction; Vaginal lubrication; Orgasm; and Sexual partner.  
Q-LES- Q 
The Q-LES-Q questionnaire is a self-reported measure designed to easily obtain sensitive 
measures of the degree of enjoyment and satisfaction experienced by subjects in various areas 
of daily functioning. It consists of 16 items on a 5-point scale; a higher score indicates a 
better result i.e. greater enjoyment or satisfaction (1 = very poor to 5 = very good). Subjects 
completed this questionnaire at the end of each week during cycles 3 (end of run-in period), 
4, 6 and 9.  
 
Safety and tolerability 
Safety and tolerability was assessed during all study visits and included vital signs, body 
weight, physical examination, safety laboratory tests (hematology and biochemistry) and 
adverse events. Any clinically relevant findings were recorded as adverse events. Skin 
characteristics related to androgens such as acne, seborrhea and hirsutism were judged 
independently by both the investigator and the participant at each study visit using a score of 
none, mild, moderate or severe. 
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Statistical analysis 
The study was not powered to find statistical differences for the questionnaires related to 
clinical outcomes. The main comparison was the change in scores from the end of the run-in 
period (Cycle 3) to the end of treatment (Cycle 9) in the DHEA group vs placebo to 
determine if any changes in sexual function and/or mood caused by COC use would improve 
after addition of DHEA (i.e. after restoration of the T levels).  Changes from baseline to the 
end of run-in period (Cycle 3) were also tested to determine the effect of COC use alone. For 
the main comparison, an analysis of covariance on log transformed values with baseline as a 
covariate was performed. The non-parametric method Kruskal-Wallis one-way analysis of 
variance was used to test whether there were differences in skin characteristics between 
groups. Results were considered to be significant at the 5% level (P < 0.05). All calculations 
were carried out using SAS (Version 9.1 for Windows) and S-PLUS (Version 7.0) statistical 
packages. 
 
Results 
 
The effect of DHEA co-administration on endocrine parameters are reported elsewhere [20]. 
The baseline demographic characteristics of the study population were comparable between 
groups for age, body mass index and ethnic origin [20].  
 
Sexual function, mood, menstrual cycle symptoms and quality of life   
MDQ 
After 3 cycles of COC use only MDQ domain scores generally improved (<50) for the 
menstrual (most recent flow) and pre-menstrual phases (4 days before most recent flow), 
except for Autonomic reactions during the menstrual phase and for Arousal (Supplemental 
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Table S2). Statistically significant improvements at the 0.05 level were found for Impaired 
concentration during all phases, for Pain during the menstrual phase and for Control during 
the inter-menstrual phase (remainder of cycle) (Supplemental Table S2). The domain Arousal 
worsened during COC for all 3 phases, with a statistically significant difference for the inter-
menstrual phase only (P < 0.001) (Supplemental Table S2).  
During co-administration of DHEA or placebo, a mixed effect was seen for 
Autonomic reactions. At the end of Cycle 9, the change (Cycle 3- Cycle 9) in the domain 
score for Autonomic reactions was statistically significantly better in the DHEA group 
compared to the placebo group for the menstrual (P = 0.05) and pre-menstrual phases  (P  
= 0.01) (Table 1; Figure 1). The change in the domain for Behavior was also significantly 
improved in the inter-menstrual phase compared to placebo (P = 0.02) (Table 1; Figure 1). A 
significant difference was found for Arousal during the pre-menstrual phase, which was in 
favor of the placebo (P = 0.01).  
 
MFSQ 
At the end of the run-in period after 3 cycles of COC use only, small and statistically 
significant decreases were found for the Global score (change from baseline to end of run-in 
period (cycle 3) -4.0 ±10.6; P = 0.002) and the domains Sexual interest (-1.7±4.5; 
P = 0.0005) and Orgasm (-1.5±3.0; P = 0.0001) (Figure 2).  
During the treatment period, no statistically significant differences were found between the 
DHEA and the placebo group  (Figure 2).  
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Q-LES-Q 
In general, mean Q-LES-Q global scores were high throughout the study i.e. during COC use 
alone and during the treatment period (≥67%) and no statistical differences were found 
between DHEA and placebo. 
 
Safety and tolerability  
No clinically relevant changes were noted for vital signs, body weight and safety laboratory 
parameters (data not shown). All reported adverse events (AEs) were of mild or moderate 
intensity. During treatment with DHEA or placebo a total of 116 AEs were reported. There 
was no difference between the treatment groups (57 for DHEA and 59 for placebo). AEs that 
were of moderate severity included hypercholesterolemia (10 in both groups) and 
hypertriglyceridemia (2 in both groups), vulvovaginal mycotic infection (one in the DHEA 
group), liver function test abnormal, anxiety, depressed mood and hirsutism (none for DHEA 
and one case per AE for the placebo group).  
 
Skin characteristics 
At baseline 20 from 99 women included showed mostly mild acne according to the 
investigator and 28 according to self-assessment. For seborrhea these number were 10 and 35 
and for hirsutism 5 and 27, respectively. During COC use only, there was an improvement of 
acne and seborrhea. Most women did not experience skin problems during the study and 
those who did, reported mild abnormalities in the majority of cases, with no reports of severe 
cases. Two women using DHEA and one using placebo reported acne as a mild AE. One 
woman treated with placebo reported hirsutism as a moderate AE. According to the 
investigator’s judgment there were no statistically significant differences between the two 
treatment groups. According to the subject’s assessment, women in the DHEA group reported 
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more cases of mild and moderate acne compared to women in the placebo group (P < 0.001). 
However, at the end of DHEA treatment compared to baseline before COC use no significant 
differences were found for all androgen related skin symptoms. Detailed results on acne are 
provided in Table 2. 
 
Discussion  
 
We have confirmed the suppression of androgen levels when using an EE/DRSP containing 
COC in a separate paper reporting the endocrine data from the present study [20]. Here we 
report the effect of this COC in healthy users without previous complaints regarding sexual 
function, mood or quality-of-life, as well as the effect of restoration of androgen levels by 
adding 50 mg DHEA to this COC, hypothesizing that such an intervention would have 
favorable clinical implications i.e. show improvements in sexual function, mood and/or 
quality of life compared to placebo (COC use alone). 
In the first part of the study small, but highly significant, negative effects of a COC 
only were observed on sexual function in the MFSQ on the Global score and the domains 
Sexual interest and Orgasm. Positive significant effects were found on menstrual cycle 
related symptoms as measured by the MDQ, except for the domain Arousal, showing 
negative effects. According to the literature, the effect of COC use on these parameters is 
inconsistent [3, 21, 23-26, 39]. In some studies the EE/DRSP COC used has been shown to 
improve the MDQ domains Water retention and Negative affect [40-42], but this was not 
observed in our study. Several publications report positive effects of EE/DRSP COCs on 
mood and sexual function [40-45], whereas others report negative effects [1, 2].  
In the second part of the study after 6 treatment cycles of the EE/DRSP COC, 
combined with either 50 mg DHEA or placebo, some small effects in favor of DHEA were 
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found on menstrual cycle related complaints in three phases of two domains of the MDQ: 
Autonomic reactions (menstrual and pre-menstrual phases), and Behavior change (inter-
menstrual phase). Placebo was better in the domain Arousal. No effect of DHEA was 
observed in the MFSQ and the Q-LES-Q. The clinical relevance of the small changes 
observed are uncertain and may even be related to multiple testing.  
The effect of COC use on mood and sexual function has been questioned [3, 21, 23-
26, 39], although in a recent paper by a group of COC experts the concept of “Oral 
Contraceptive-Associated Sexual Dysfunction” has been presented [4]. The COC only data 
from our study support the view that COC use may have a negative effect on sexual function. 
Only a few studies report combined investigations of the effect of COCs on androgens and 
the occurrence of behavioral side effects and those studies also report conflicting results [1, 2, 
5, 27, 46-51]. Potential reasons for these inconsistences include differences in subject 
characteristics such as age, BMI, genetic factors including individual sensitivities to androgen 
reduction, and differences in study design such as endpoints, type of oral contraception and 
duration of treatment [3, 5, 15, 27].  
There may be several other explanations for the questionable clinical effects of DHEA 
in the present study. First, the study was powered to evaluate the effect of DHEA on the 
levels of total T and not to find statistical differences for the questionnaires used. Therefore, 
the group sizes may have been too small to reach statistical significance. This is supported by 
the observation of many trends in favor of DHEA in this study (Figures 1 and 2). Second, a 
potential inclusion bias is that those women who are sensitive to testosterone changes and 
have experienced such changes during earlier COC use, may not have volunteered to 
participate in this study. Third, the sensitivity of the questionnaires used may have been too 
low to find subtle behavioral differences in healthy young women without complaints. In 
another study we have used a sexual function diary, which appeared to be more sensitive, as 
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demonstrated in a study on sexual function in postmenopausal women [52]. Fourth, the 
endocrine effect of the 50 mg dose of DHEA may have been insufficient in combination with 
the EE/DRSP COC used, due to the strong increase of SHBG that binds T and interferes with 
an adequate increase of free T [20]. Full restoration of total T levels to baseline levels was 
achieved, but free T levels were only restored by 47%. For an optimal judgment of the 
clinical effects of normalizing T during COC use, it may be necessary to restore free T 
completely.  
This raises the issue of the DHEA dose used. A daily dose of 50 mg DHEA was 
chosen, based on earlier dose-finding studies in elderly individuals with normal levels of 
SHBG and not using other drugs [29]. In addition, we have shown earlier that a dose of 
50 mg DHEA could normalize free T levels in combination with a COC containing the 
progestin levonorgestrel (LNG) [53]. COCs containing LNG hardly increase SHBG [19] and 
therefore, the clinical effect of androgen restoration in users of an EE/LNG COC by adding 
50 mg DHEA may be more pronounced. For those COCs that increase SHBG, a higher dose 
of DHEA may be required to normalize free T and demonstrate clinical effects. However, a 
higher DHEA dose will also increase the levels of ADG further, which may enhance 
androgenic effects on the skin.  
In this study, the daily co-administration of 50 mg DHEA did not give rise to safety 
concerns, as supported by data from the literature [54-61]. As demonstrated also in this study 
COCs improve androgenic skin symptoms and an important question was whether DHEA use 
would have negative effects on androgen related skin symptoms. COCs act by reducing 
androgen levels and by blocking the androgen receptors [62-66]. COCs may also inhibit the 
activity of skin 5α -reductase, which results in a reduction of the conversion from T to DHT 
[65, 67, 68]. Despite a significant increase of ADG in the current study, the co-treatment with 
DHEA did not worsen skin symptoms, but it negated the beneficial effect of the COC on acne 
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partially according to the judgment of the investigator and completely according to the self-
assessment of the subjects. Therefore it seems advisable not to use an androgen restored COC 
in women with androgen related skin characteristics.  
In conclusion, the 50 mg dose of DHEA used in this study may have been too low for 
this particular COC, since levels of free T were only restored by 47% compared to baseline 
before COC use. A well-balanced judgment of the clinical consequences of the concept of 
normalizing androgens during COC use may require complete normalization of free T, lost 
for 86% due to COC use in this study.  
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Table 1: Effect of 50 mg DHEA or placebo daily co-administration on menstrual cycle symptoms as measured by the Moos Menstrual Distress Questionnaire 
(MDQ), scores for the domains Pain, Autonomic reactions, Negative affect, Behavior change, and Arousal during different phases of the cycle, in women 
using a COC containing 30 μg ethinylestradiol and 3 mg drospirenone 
  Menstrual phase  Pre-menstrual phase  Inter-menstrual phase 
Variable Treatment Cycle 3 Cycle 9 Change from 
cycle 3 to 
cycle 9 
 Cycle 3 Cycle 9 Change from 
cycle 3 to 
cycle 9 
 Cycle 3 Cycle 9 Change from 
cycle 3 to 
cycle 9 
Pain DHEA 45.0±12.6 42.8±10.6 -2.0±13.0  47.3±13.1 45.4±9.5 -2.1±12.4  50.0±15.1 49.2±10.5 -0.9±14.2 
Placebo 49.3±17.2 48.0±16.0 -1.1±14.7  48.9±16.0 48.8±14.0 -0.8±9.0  51.3±20.7 54.0±16.4 3.7±18.2 
Autonomic 
reactions 
DHEA 46.7±10.6 44.8±9.2 -2.0±11.5*  48.2±13.2 45.0±5.0 -3.1±11.1**  49.1±7.9 48.8±8.4 -0.5±10.5 
Placebo 50.6±15.1 50.7±14.8 0.7±11.6  49.2±12.1 51.3±16.6 2.9±17.2  54.9±18.8 51.3±13.4 -2.3±22.5 
Negative 
affect 
DHEA 45.7±15.8 42.1±14.0 -4.2±14.8  45.4±13.0 43.4±12.2 -2.8±12.9  48.3±11.1 46.5±14.3 -3.1±14.2 
Placebo 46.4±12.9 45.4±15.3 -0.8±15.2  45.3±12.0 45.9±13.4 0.8±13.6  47.6±15.3 50.2±16.4 2.1±20.5 
Behavior 
change 
DHEA 47.0±9.7 46.0±12.6 -1.7±12.2  48.8±12.0 49.0±14.8 -0.5±15.6  51.1±11.6 50.8±14.6 -1.4±14.6* 
Placebo 54.6±16.9 51.7±19.5 -2.7±17.8  55.6±19.2 55.9±19.9 0.8±18.3  57.8±24.3 60.4±25.2 3.6±32.3 
Arousal DHEA 46.2±13.9 42.7±11.4 -3.4±10.2  47.3±14.6 42.1±10.2 -5.0±9.3**  46.4±13.4 42.6±9.6 -3.7±10.9 
Placebo 45.6±12.0 43.9±11.3 -1.0±11.7  46.3±12.5 46.5±13.9 1.0±13.2  45.4±11.6 44.3±9.7 -0.6±9.8 
Data are expressed as mean ± standard deviation; cycle 3 = the end of the run in period with COC alone; cycle 9 = end of treatment period; bold*=P < 0.05 
between the two treatment groups (DHEA vs placebo) at cycle 9 with regard the change from cycle 3 (COC use alone); bold**=P < 0.01 between the two treatment 
groups (DHEA vs placebo) at cycle 9 with regard the change from cycle 3 (COC use alone); COC, combined oral contraception; DHEA, dehydroepiandrosterone; n, 
number  
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Table 2.  Effect of 50 mg DHEA daily co-administration compared to placebo on skin characteristics in women using a COC 
containing 30 μg ethinylestradiol and 3 mg drospirenone 
Variable Treatment Assessment  Baseline End of run-in period 
(Cycle 3: COC only) 
Treatment period 
(Cycle 6) 
End of treatment period 
(Cycle 9) 
Acne DHEA Investigator n 49 49 49 49 
   none  37 47 45 42 
   mild 12 2 4 7 
   moderate 0 0 0 0 
 
  
severe 0 0 0 0 
 Subject n 49 49 49 49 
   none  32 40 37 34 
   mild 15 9 9 13 
   moderate 2 0 3 2 
   severe 0 0 0 0 
 Placebo Investigator n 50 50 48 48 
   none  42 46 45 45 
   mild 7 3 3 3 
   moderate 1 1 0 0 
   severe 0 0 0 0 
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  Subject n 50 50 48 48 
 
  
none  39 38 43 42 
 
  
mild 10 11 4 6 
 
  
moderate 1 1 1 0 
 
  
severe 0 0 0 0 
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Figure 1.  Effect of COC use alone and of 50 mg dehydroepiandrosterone (DHEA) daily co-
administration on menstrual cycle symptoms as measured by the Moos Menstrual Distress 
Questionnaire (MDQ), scores for the domains Pain, Autonomic reactions, Negative affect and 
Impaired concentration during different phases of the cycle, in women using a COC containing 30 μg 
ethinylestradiol and 3 mg drospirenone. In these box plots, half of the data (percentile 25-75) is 
represented by the boxes. Dark dashed lines in the boxes indicate the median. T-bars from the boxes 
extend to the minimum and maximum; COC, combined oral contraceptive.  
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Figure 2.  Effect of COC use alone and of 50 mg dehydroepiandrosterone (DHEA) daily co-
administration on female sexual function as measured by the McCoy Female Sexuality Questionnaire 
(MFSQ) for the Global score and the domains Orgasm, Sexual interest and Vaginal lubrication in 
women using a COC containing 30 μg ethinylestradiol and 3 mg drospirenone. In these box plots, half 
of the data (percentile 25-75) is represented by the boxes. Dark dashed lines in the boxes indicate the 
median. T-bars from the boxes extend to the minimum and maximum; COC, combined oral 
contraceptive.  
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